Paradigm Biopharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Bankr. Admin/Reorg
- Financing Rounds
-
8
- Investments
-
1
Paradigm Biopharmaceuticals General Information
Description
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS. Its activities are conducted across Australia, the United States, Hong Kong, and Moldova through global clinical development programs and strategic research collaborations.
Contact Information
Website
www.paradigmbiopharma.comCorporate Office
- Level 15, 500 Collins Street
- Melbourne, Victoria 3000
- Australia
Corporate Office
- Level 15, 500 Collins Street
- Melbourne, Victoria 3000
- Australia
Paradigm Biopharmaceuticals Timeline
Paradigm Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Paradigm Biopharmaceuticals Patents
Paradigm Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023902506-A0 | Treatment of mucopolysaccharidosis | Pending | 08-Aug-2023 | ||
| AU-2023901505-A0 | Chemical pps modification | Pending | 16-May-2023 | ||
| AU-2023901503-A0 | Pps conjugates | Pending | 16-May-2023 | ||
| AU-2022902567-A0 | Treatment of psoriasis, psoriatic arthritis and dermatitis | Pending | 06-Sep-2022 | ||
| AU-2023337133-A1 | Treatment of psoriasis, psoriatic arthritis and dermatitis | Pending | 06-Sep-2022 | A61K31/737 |
Paradigm Biopharmaceuticals Acquisitions (1)
Paradigm Biopharmaceuticals’s most recent deal was a Merger/Acquisition with Proteobioactives for . The deal was made on 30-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Proteobioactives | 30-Sep-2025 | Merger/Acquisition | Drug Discovery |
Paradigm Biopharmaceuticals FAQs
-
When was Paradigm Biopharmaceuticals founded?
Paradigm Biopharmaceuticals was founded in 2014.
-
Where is Paradigm Biopharmaceuticals headquartered?
Paradigm Biopharmaceuticals is headquartered in Melbourne, Australia.
-
What industry is Paradigm Biopharmaceuticals in?
Paradigm Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is Paradigm Biopharmaceuticals a private or public company?
Paradigm Biopharmaceuticals is a Private company.
-
What is Paradigm Biopharmaceuticals’s current revenue?
The current revenue for Paradigm Biopharmaceuticals is .
-
How much funding has Paradigm Biopharmaceuticals raised over time?
Paradigm Biopharmaceuticals has raised $103M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process